• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
172684 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州

$ B% T  |5 e% D5 `0 _& s4 e' k可以,但要有针对性,
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
! X: p& {) ^( `, d: F, V
1 Z/ V* x3 `% c* |4 a+ w; @6 t) ~& E
6 D& ?, s/ h- F* Z$ }Sub-category:
2 d6 _# a% e; n! ?Molecular Targets
. n5 I  ~5 ~* H; A  Y; L; c1 @
  ~( h2 h1 E& Z& [0 S; M9 X6 U; ?
3 O' F+ |# |5 }7 e( V& u, A7 g$ {Category:
9 I) ^7 V2 N1 I8 ITumor Biology
7 Q. x5 F3 D( J. S' }. t+ p& B$ ]8 x! {
0 z* R6 \# z# P! R' Z7 C) _+ c) |2 r  Q3 l( P0 s
Meeting:3 h% K5 `/ V. C+ d0 \
2011 ASCO Annual Meeting 4 W8 s8 Q  D$ p1 l: c: ^) l! O

+ j1 O- K, Z0 f- f: I9 n6 ^2 W) \+ x& P  z
Session Type and Session Title:: W) Z9 a* d/ M
Poster Discussion Session, Tumor Biology - o8 f! h9 R9 T
, G( d( p% K( Y2 u" ]  B! X; B7 N+ }1 m
- P6 k& \$ ~: |) h  r4 U) F
Abstract No:2 H  M- D. S5 l: h8 C0 t# ]
10517
% x" u- \! \/ q
) ]. M, s, W- p
) W% h7 ]/ \1 R; \  \, k' h$ |, FCitation:1 ~1 `; [( d4 d
J Clin Oncol 29: 2011 (suppl; abstr 10517)
* z5 ^, l5 F) X- E- t/ E2 ~$ ~! p& U. \# \% P% X! J) i

9 e: j( E& W4 w+ E5 y# JAuthor(s):
1 o: I. q6 @- f0 G& f- N9 RJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
1 P) |/ m+ A: o% O) \; x' n1 S
# n  Z% {3 E& M9 t+ p( X
6 s) c! R4 @- D5 z  Z3 R1 k4 Z3 T" o% }& q8 v9 ^' w5 k
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.0 C  d, p2 F. `: _6 @

: E5 w% v* ]+ o6 J8 sAbstract Disclosures" y2 u: p. k( d" u1 ~5 y" Z" D

! q; }& y7 M; G4 \, g; D' cAbstract:
" R( S+ m. o1 Y' w9 T5 j  N8 k! Y7 c' |+ v

9 q9 I: @$ A0 ?- b  u! |Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
) \# o$ q0 {& ^# l$ I3 y: r4 \) Y8 p0 n% l  R- N. M% F
5 H) n- [) `3 k& W
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
4 h1 D+ t9 s5 f' u0 z9 U, {( l没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
' v% _/ H* v- i9 v# n+ h
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
3 T3 [$ z# z0 b+ r7 @易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
  A( }) D0 ], V/ I8 y# R; _ALK一个指标医院要900多 ...

0 d& z, C+ Y; w0 P6 {! a- ?" M平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
- B# t" I$ q& d, v9 G
. t" \' w. E% i# Q% G% A现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表